Free Trial
Final Hours! MarketBeat All Access at $149 Until 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion
NASDAQ:CORT

Corcept Therapeutics Q3 2026 Earnings Date & Estimates

Corcept Therapeutics logo
$85.95 -0.33 (-0.38%)
Closing price 10/29/2026 04:00 PM Eastern
Extended Trading
$85.59 -0.36 (-0.42%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Corcept Therapeutics in Q3 2026

Corcept Therapeutics is expected to post earnings of $0.7940 per share on revenue of $323.90 million. In the same quarter a year earlier Corcept Therapeutics reported $0.16 per share on revenue of $207.64 million. Corcept Therapeutics last reported on July 29, 2026, posting $0.36 per share and beating the $0.0243 consensus estimate. Corcept Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.7940
Expected Revenue
$323.90 million
Prior-Year EPS
$0.16
Prior-Year Revenue
$207.64 million
Expected EPS Growth
+396.3%
Expected Revenue Growth
+56.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.36 (Beat by +$0.3357)
Last Quarter Revenue
$256.15 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Corcept Therapeutics Q3 2026 Earnings FAQ

Corcept Therapeutics (NASDAQ:CORT) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Corcept Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Corcept Therapeutics to post earnings of $0.7940 per share for Q3 2026.

The consensus revenue estimate for Corcept Therapeutics is $323.90 million for Q3 2026.

Corcept Therapeutics Earnings Headlines

Corcept Reports Positive Phase 2 BELLA Results For Lifyorl In Platinum-Resistant Ovarian Cancer
October 28 at 12:37 PM  |  rttnews.comhttps://www.rttnews.com/3702925/corcept-reports-positive-phase-2-bella-results-for-lifyorl-in-platinum-resistant-ovarian-cancer.aspx
Corcept Therapeutics Incorporated Reports Positive Results from Phase 2 Bella Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum ...
October 26, 2026  |  marketscreener.comM
Federal Reserve’s Disturbing Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel
 |  Weiss Ratings (Ad)
Corcept Therapeutics Says Trial of Lifyorli Combination Slows Ovarian Cancer Growth
October 26, 2026  |  marketscreener.comM
Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study
October 26, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/10/62596651/corcept-reports-favorable-survival-and-response-data-in-ovarian-cancer-study
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
October 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/corcept-reports-positive-results-phase-120000347.html
See More Corcept Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Corcept Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corcept Therapeutics and other key companies, straight to your email.

About Corcept Therapeutics

Corcept Therapeutics (NASDAQ:CORT) (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery. The company also has a pipeline of investigational therapies, including relacorilant, a selective glucocorticoid receptor modulator being evaluated in Cushing’s syndrome and other conditions associated with cortisol activity.

Founded in 1998, Corcept is headquartered in Menlo Park, California. Its activities include drug discovery, clinical development, regulatory work and commercialization, with its products and clinical programs primarily serving patients and healthcare providers in the United States while its research programs may involve international clinical sites. Joseph K. Belanoff, M.D., a co-founder of the company, has served as Corcept’s chief executive officer.

View Corcept Therapeutics Profile
Earnings Tools